Answers are grounded in this paper and cite their sources.
Objectives To map the systemic and oral adverse events (AEs) of semaglutide reported in randomized controlled trials (RCTs). Data This scoping review was conducted following the PRISMA-ScR guidelines. Only english-language and RCTs were considered. Sources A literature search was conducted in PubMed, Scopus, and Web of Science from 2019 until 2025. Study selection Of 630 identified records (300 in PubMed, 312 in Scopus, and 18 in Web of Science), 12 studies were included after screening. The review identified systemic AEs of semaglutide, primarily gastrointestinal events like nausea (12 studies) and diarrhea (11 studies). Less frequent effects included pancreatitis (5 studies), hepatobiliary (3 studies) and gallbladder disease (3 studies), dental caries (1 study) and dry mouth (1 study). Subcutaneous administration predominating (7 studies), followed by oral (3) and mixed routes (2), over treatment durations of 21–68 weeks and 4–9 weeks of follow-up. Additionally, systemic events such as nasopharyngitis (5 studies), COVID-19 (5 studies), and metabolic or nutrition-related disorders were reported in all 12 studies. Importantly, none of the included studies directly investigated oral or dental outcomes. Conclusions Semaglutide demonstrated an overall favorable safety profile in the included randomized controlled trials, with adverse events predominantly gastrointestinal. However, the RCTs did not provide direct evidence regarding oral health outcomes. Therefore, the available evidence is insufficient to draw conclusions about oral adverse events associated with semaglutide, highlighting the need for randomized clinical trials specifically designed to assess oral health outcomes in patients receiving GLP-1 receptor agonists.
No takes yet. Share an insight, caveat, or question.
Muknickas et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: